AI Imaging at RSNA 2025: What GE HealthCare's Momentum Means for Care Delivery and the GEHC Thesis
GE HealthCare used RSNA 2025 to bring forward new CT, MRI, mammography, and radiology workflow platforms built around AI and cloud integration. The practical throughline: smoother workflows, tighter image quality control, and a path to more consistent precision care. Alongside product news, the company noted fresh FDA authorizations and recent fixed-income offerings to support the roadmap.
What GE HealthCare announced
- AI-driven upgrades across CT, MRI, and mammography to improve image reconstruction and consistency.
- Radiology workflow tools and cloud services aimed at reducing bottlenecks from scheduling to reporting.
- FDA progress, including premarket authorization for Pristina Recon DL in 3D mammography at lower radiation doses.
- Fixed-income funding to back product development and commercialization.
Why this matters for clinical teams
- More consistent image quality and reconstruction can reduce repeat scans and help optimize dose management.
- AI-assisted workflows may shorten time to read, support triage, and reduce manual steps that slow throughput.
- Cloud delivery can centralize updates and scale tools across multi-site systems without heavy on-prem lift.
The FDA milestone to watch
Pristina Recon DL received FDA premarket authorization, bringing deep-learning-based 3D mammography that targets better cancer detection at lower doses. For breast programs, that combination can influence screening compliance, image quality confidence, and total exam time. As with any imaging advance, local validation, training, and QA will determine real-world gains. For context, see the FDA premarket approval process.
The near-term risk that hasn't gone away
Tariffs remain the primary headwind called out by management and external analyses. They can pressure device margins, complicate pricing, and influence capital budget timing. Competitive intensity and shifting regulatory expectations add more variability. None of the RSNA news changes those facts.
The investment setup in plain terms
Forecasts point to about $22.7 billion in revenue and $2.5 billion in earnings by 2028. That's roughly 4.3% annual revenue growth and a step-up from about $2.2 billion in earnings today. One valuation view lands near $89.21 per share, implying about 13% upside from the referenced price at the time of the analysis. Community fair values span a wide range (about $62 to $125), reflecting uncertainty tied to tariffs, adoption pace, and pricing sustainability.
What healthcare leaders should track next
- Peer-reviewed evidence: sensitivity/specificity, dose reductions, and throughput impact for new imaging and reconstruction tools.
- Regulatory cadence: additional FDA filings and timelines across CT, MRI, and breast imaging updates.
- Total cost of ownership: service terms, cloud fees, cybersecurity safeguards, and staff training time.
- Integration: interoperability with PACS/RIS/EHR, orchestration with existing worklists, and single sign-on.
- Reimbursement: any coding or coverage updates that could influence adoption and ROI.
- Tariff and procurement policies: budget sensitivity for capital cycles and multisite standardization plans.
Clinical takeaways
- Lower-dose 3D mammography with AI reconstruction is clinically meaningful if outcomes and workflow data hold up in your setting.
- Cloud-based workflow tools can reduce friction, but require clear governance on data, security, and change management.
- Pilot first, measure throughput and diagnostic yield, then scale with service-level guarantees.
Resources
This commentary is general and educational. It is not financial advice or a recommendation to buy or sell any security. Always consider your organization's objectives, constraints, and clinical standards before making procurement or investment decisions.
Your membership also unlocks:
